scholarly article | Q13442814 |
P356 | DOI | 10.1212/WNL.40.10.1529 |
P698 | PubMed publication ID | 2215943 |
P2093 | author name string | Huber S | |
Gauthier S | |||
McDermott M | |||
Carter J | |||
Jankovic J | |||
Shoulson I | |||
Koller W | |||
Goetz C | |||
Golbe L | |||
Olanow C | |||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Parkinson's disease | Q11085 |
P304 | page(s) | 1529-1534 | |
P577 | publication date | 1990-10-01 | |
P1433 | published in | Neurology | Q1161692 |
P1476 | title | Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group | |
P478 | volume | 40 |
Q36885946 | A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis |
Q48847429 | A comparison of LEDD and motor scores following STN-DBS treatment in patient with young onset vs. late onset Parkinson's disease. |
Q31919970 | A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes |
Q34628386 | A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes |
Q50282977 | A longitudinal study of parkinsonism and disability in a community population of older people. |
Q30482570 | A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease |
Q47571451 | APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease |
Q38663184 | Aberrant Intrinsic Activity and Connectivity in Cognitively Normal Parkinson's Disease |
Q35744871 | Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression. |
Q64883946 | Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism. |
Q39500448 | Acoustic evaluation of short-term effects of repetitive transcranial magnetic stimulation on motor aspects of speech in Parkinson's disease. |
Q48663441 | Activities of daily living and quality of life in persons with newly diagnosed Parkinson's disease according to subtype of disease, and in comparison to healthy controls. |
Q47115737 | Addenbrooke's Cognitive Examination-Revised is accurate for detecting dementia in Parkinson's disease patients with low educational level |
Q33403235 | Advanced time-series analysis of MEG data as a method to explore olfactory function in healthy controls and Parkinson's disease patients |
Q36065012 | Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease |
Q91642330 | Altered Body Composition and Increased Resting Metabolic Rate Associated with the Postural Instability/Gait Difficulty Parkinson's Disease Subtype |
Q42097113 | Altered Functional Connectivity Density in Subtypes of Parkinson's Disease |
Q58571784 | Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease |
Q34080479 | Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease |
Q50279506 | Ambulatory motor assessment in Parkinson's disease. |
Q49154837 | Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia |
Q28552902 | An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia |
Q61813331 | An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression |
Q92489442 | An update on the management of young-onset Parkinson's disease |
Q55215632 | Analysis of Single Nucleotide Polymorphisms of STK32B, PPARGC1A and CTNNA3 Gene With Sporadic Parkinson's Disease Susceptibility in Chinese Han Population. |
Q94460500 | Analysis of non-invasive gait recording under free-living conditions in patients with Parkinson's disease: relationship with global cognitive function and motor abnormalities |
Q64865092 | Analysis of the clinical features of early Parkinson's disease with comparatively integrated intestinal function |
Q24201127 | Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases |
Q24242944 | Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases |
Q36419572 | Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis |
Q39874201 | Anxiety disorders in Parkinson's disease: prevalence and risk factors |
Q47948376 | Apathy and associated factors in Mexican patients with Parkinson's disease |
Q91667004 | Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS) |
Q41355527 | Arm swing as a potential new prodromal marker of Parkinson's disease |
Q34432509 | Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease |
Q36217232 | Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese. |
Q33688838 | Association of Parkinson disease risk loci with mild parkinsonian signs in older persons |
Q33666297 | Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease |
Q37433956 | Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans |
Q31095916 | Automatic Classification on Multi-Modal MRI Data for Diagnosis of the Postural Instability and Gait Difficulty Subtype of Parkinson's Disease |
Q50267171 | Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. |
Q34640956 | Axial kinesthesia is impaired in Parkinson's disease: effects of levodopa |
Q46965498 | Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort |
Q72030426 | Behavioral Relaxation Training for tremor disorders in older adults |
Q26747010 | Benign tremulous Parkinsonism: a unique entity or another facet of Parkinson's disease? |
Q47992471 | Benign tremulous parkinsonism in a patient with dardarin mutation |
Q48922616 | Bereitschaftspotential in depressed and non-depressed patients with Parkinson's disease |
Q45292387 | Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease |
Q34733143 | Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease |
Q38413629 | Beyond verbal fluency: investigating the long-term effects of bilateral subthalamic (STN) deep brain stimulation (DBS) on language function in two cases |
Q49942492 | Biomarkers for Parkinson's Disease: Recent Advancement. |
Q48754933 | Boxing Training for Patients With Parkinson Disease: A Case Series |
Q36616565 | COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease prog |
Q37272860 | CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study |
Q27304608 | CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease |
Q33994583 | CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease |
Q50278543 | Cardiac 123I-MIBG scintigraphy in patients with essential tremor. |
Q48125076 | Cerebral atrophy in Parkinson's disease patients with visual hallucinations. |
Q36410997 | Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? |
Q26744782 | Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease |
Q39866469 | Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers |
Q58763366 | Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders |
Q47657093 | Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features |
Q50249498 | Change in plasma levels of amino acid neurotransmitters and its correlation with clinical heterogeneity in early Parkinson's disease patients. |
Q39411963 | Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease |
Q34517430 | Changes in motor subtype and risk for incident dementia in Parkinson's disease |
Q48085926 | Changing panoramas and new horizons in Parkinson's disease |
Q64910875 | Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson's Disease. |
Q57265610 | Classification of Pediatric Asthma: From Phenotype Discovery to Clinical Practice |
Q56504087 | Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology |
Q39440179 | Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases |
Q47639038 | Clinical Profile of Chinese Long-Term Parkinson's Disease Survivors With 10 Years of Disease Duration and Beyond |
Q36447155 | Clinical and Epidemiological Factors Associated with Mortality in Parkinson's Disease in a Brazilian Cohort. |
Q41652372 | Clinical and Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with Lewy Bodies |
Q36815103 | Clinical characteristics in early Parkinson's disease in a central California population-based study |
Q30445877 | Clinical characteristics with an impact on ADL functions of PD patients with cognitive impairment indicative of dementia |
Q33861294 | Clinical correlates of depressive symptoms in familial Parkinson's disease |
Q48345527 | Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson's disease. |
Q35199149 | Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis |
Q40860918 | Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease |
Q39782935 | Clinical subtypes of Parkinson's disease |
Q39170813 | Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study |
Q61803900 | Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders |
Q30975753 | Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry |
Q47774821 | Cognitive function and other non-motor features in non-demented Parkinson's disease motor subtypes |
Q40540982 | Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. |
Q38416865 | Cognitive function in the early phase of Parkinson's disease, a five-year follow-up |
Q36226772 | Cognitive impairment in Parkinson's disease |
Q48415374 | Cognitive impairment in early-stage non-demented Parkinson's disease patients |
Q48251456 | Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. |
Q35938554 | Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. |
Q35693083 | Colonic bacterial composition in Parkinson's disease. |
Q50265173 | Color vision in Parkinson's disease and essential tremor. |
Q37572904 | Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype |
Q38799418 | Comparison of Pallidal and Subthalamic Deep Brain Stimulation in Parkinson's Disease: Therapeutic and Adverse Effects |
Q90135146 | Complexity of electrocortical activity as potential biomarker in untreated Parkinson's disease |
Q42547717 | Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders |
Q33691370 | Conjugal Parkinsonism and Parkinson disease: a case series with environmental risk factor analysis. |
Q36337189 | Contribution of inter-muscular synchronization in the modulation of tremor intensity in Parkinson's disease. |
Q30276836 | Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction |
Q40694830 | Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality |
Q38140018 | Current status of safinamide for the drug portfolio of Parkinson's disease therapy |
Q61443369 | Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study |
Q52037004 | Declarative and procedural learning in Parkinson's disease patients having tremor or bradykinesia as the predominant symptom. |
Q41597087 | Decreased interhemispheric functional connectivity in subtypes of Parkinson's disease. |
Q38639708 | Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. |
Q30843485 | Default mode network differences between rigidity- and tremor-predominant Parkinson's disease |
Q57306397 | Dementia with Lewy bodies |
Q92227050 | Detection of orthostatic hypotension with ambulatory blood pressure monitoring in parkinson's disease |
Q110950278 | Detection of sitting posture using hierarchical image composition and deep learning |
Q37665022 | Diagnosis and referral delay in women with Parkinson's disease |
Q48432391 | Diagnostic aspects of early Parkinson's disease |
Q45265173 | Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease |
Q36818397 | Differences in brain activation between tremor- and nontremor-dominant Parkinson disease |
Q48762323 | Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease |
Q40521399 | Different patterns of spontaneous brain activity between tremor-dominant and postural instability/gait difficulty subtypes of Parkinson's disease: a resting-state fMRI study. |
Q42952837 | Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson's disease |
Q41517891 | Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease |
Q34629923 | Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease |
Q30418344 | Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease |
Q92309534 | Differentiating Parkinson's disease motor subtypes using automated volume-based morphometry incorporating white matter and deep gray nuclear lesion load |
Q49119028 | Diffusion tensor imaging and correlations to Parkinson rating scales. |
Q36161362 | Digitized Spiral Drawing: A Possible Biomarker for Early Parkinson's Disease |
Q36779123 | Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease |
Q48117050 | Disrupted Brain Network Hubs in Subtype-Specific Parkinson's Disease |
Q34376763 | Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study |
Q34757659 | Distinguishing patients with Parkinson's disease subtypes from normal controls based on functional network regional efficiencies |
Q47776026 | Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study |
Q51967394 | Does motor subtype influence neurocognitive performance in Parkinson's disease without dementia? |
Q50091830 | Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease |
Q58090376 | Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study |
Q36983484 | Effect of a Leucine-rich Repeat Kinase 2 Variant on Motor and Non-motor Symptoms in Chinese Parkinson's Disease Patients |
Q33950517 | Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease |
Q35469220 | Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease |
Q51293844 | Effects of random whole-body vibration on postural control in Parkinson's disease. |
Q37559961 | Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson's disease |
Q77599277 | Epidemiological studies: risk factors session IV summary and research needs |
Q64944300 | Epidemiology of Parkinson's disease |
Q58711666 | Evaluation of dysphagia in different phenotypes of early and idiopathic Parkinsonism |
Q64098776 | Evaluation of tremor interference with control of voluntary reaching movements in patients with Parkinson's disease |
Q36834550 | Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. |
Q64094056 | Exploring the association between Cerebral small-vessel diseases and motor symptoms in Parkinson's disease |
Q38173746 | Exploring the cognitive and motor functions of the basal ganglia: an integrative review of computational cognitive neuroscience models |
Q53835351 | Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson's disease. |
Q51947999 | Extended testing across, not within, tasks raises diagnostic accuracy of smell testing in Parkinson's disease. |
Q33750089 | Factors predicting the instant effect of motor function after subthalamic nucleus deep brain stimulation in Parkinson's disease |
Q33818930 | Falling Direction can Predict the Mechanism of Recurrent Falls in Advanced Parkinson's Disease |
Q92991163 | Falls in Parkinson's Disease Subtypes: Risk Factors, Locations and Circumstances |
Q36608484 | Familial Aggregation and Co-Aggregation of Essential Tremor and Parkinson's Disease |
Q34300040 | Familial aggregation of Parkinson's disease in a multiethnic community‐based case‐control study |
Q39175171 | Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia |
Q61046071 | Familial aggregation of early- and late-onset Parkinson's disease |
Q36541534 | Familial aggregation of panic disturbances in Parkinson's disease |
Q64065685 | Feasibility of Home-Based Automated Assessment of Postural Instability and Lower Limb Impairments in Parkinson's Disease |
Q42610878 | Finger tapping movements of Parkinson's disease patients automatically rated using nonlinear delay differential equations. |
Q35650547 | Five times sit-to-stand test performance in Parkinson's disease |
Q34625773 | Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy |
Q48795933 | Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study |
Q50254742 | Frequencies of falls and associated features at different stages of Parkinson's disease |
Q35897974 | Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study |
Q39552785 | Frontal white matter injuries predestine gait difficulties in Parkinson's disease |
Q35487919 | Functional improvement after subthalamic stimulation in Parkinson's disease: a non-equivalent controlled study with 12-24 month follow up. |
Q46858173 | Functional neuroimaging of motor control in Parkinson's disease: a meta-analysis |
Q33861662 | Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson's disease: a case control study |
Q50246695 | Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations |
Q44670565 | Gait dysfunction in Parkinson's disease and normal pressure hydrocephalus: a comparative study |
Q50265124 | Gait in SWEDDs patients: comparison with Parkinson's disease patients and healthy controls. |
Q50782036 | Gait patterns in Parkinsonian patients with or without mild cognitive impairment. |
Q47750459 | Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson's disease |
Q92620973 | Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson's disease |
Q37374495 | Global cognitive function and processing speed are associated with gait and balance dysfunction in Parkinson's disease |
Q36870270 | Gray matter atrophy distinguishes between Parkinson disease motor subtypes |
Q35492461 | Gut microbiota are related to Parkinson's disease and clinical phenotype |
Q92915189 | Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression |
Q50245412 | Heart rate variability shows different cardiovascular modulation in Parkinson's disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype. |
Q30982993 | Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. |
Q48851886 | High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease |
Q48906942 | Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia |
Q35012559 | Home and health in people ageing with Parkinson's disease: study protocol for a prospective longitudinal cohort survey study |
Q38381455 | How do cognitive and axial motor signs correlate in Parkinson's disease? A 6-year prospective study. |
Q45749689 | Identifying axial and cognitive correlates in patients with Parkinson's disease motor subtype using the instrumented Timed Up and Go. |
Q37738514 | Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease |
Q43583704 | Impaired oculomotor function in a community-based patient population with newly diagnosed idiopathic parkinsonism |
Q57514578 | Impaired self-awareness of motor deficits in Parkinson's disease: Association with motor asymmetry and motor phenotypes |
Q47986710 | Impairment of post-movement beta synchronisation in parkinson's disease is related to laterality of tremor. |
Q35838028 | Improving community healthcare for patients with Parkinson's disease: the dutch model |
Q46245987 | In vivo gastric detection of α-synuclein inclusions in Parkinson's disease. |
Q64246494 | Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study |
Q35190139 | Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders |
Q98464862 | Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson's Disease |
Q48347361 | Increased cerebral activity in Parkinson's disease patients carrying the DRD2 TaqIA A1 allele during a demanding motor task: a compensatory mechanism? |
Q35745128 | Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients |
Q47901306 | Inhibitory motor dysfunction in parkinson's disease subtypes |
Q62719917 | Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease |
Q36966066 | Is PIGD a legitimate motor subtype in Parkinson disease? |
Q90751092 | Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial |
Q46098287 | LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation |
Q36390860 | Late-life depression: a neuropsychiatric approach |
Q35163173 | Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease |
Q48167923 | Levodopa response differs in Parkinson's motor subtypes: A task-based effective connectivity study. |
Q64862824 | Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease |
Q39578837 | Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease |
Q39079510 | Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. |
Q37228718 | Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease |
Q39466212 | Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression. |
Q48824050 | Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. |
Q48172859 | Longitudinal study of levodopa in Parkinson's disease: effects of the advanced disease phase |
Q42523676 | Low-pass filter properties of basal ganglia cortical muscle loops in the normal and MPTP primate model of parkinsonism |
Q36328177 | Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype. |
Q48848879 | MEG resting state functional connectivity in Parkinson's disease related dementia |
Q38761858 | Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations |
Q50055484 | Measurement of Axial Rigidity and Postural Instability Using Wearable Sensors |
Q38592102 | Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes. |
Q99609969 | Mining genetic and transcriptomic data using machine learning approaches in Parkinson's disease |
Q60958335 | Monitoring Motor Symptoms During Activities of Daily Living in Individuals With Parkinson's Disease |
Q37092071 | More Time with Tremor: The Experience of Essential Tremor Versus Parkinson's Disease Patients |
Q48742896 | Morphological differences in Parkinson's disease with and without rest tremor |
Q35970595 | Motor Subtype as a Predictor of Future Working Memory Performance in Idiopathic Parkinson's Disease |
Q53417465 | Motor Subtypes of Parkinson's Disease Can Be Identified by Frequency Component of Postural Stability. |
Q39841718 | Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease |
Q50263828 | Motor imagery evokes increased somatosensory activity in Parkinson's disease patients with tremor |
Q38739709 | Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex |
Q34589859 | Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies |
Q33723751 | Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease |
Q34513753 | Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies |
Q38654691 | Motor subtype changes in early Parkinson's disease. |
Q38844581 | Motor subtype in Parkinson's disease: Different disorders or different stages of disease? |
Q43448082 | Motor symptoms after deep brain stimulation of the subthalamic nucleus |
Q82029376 | Motor symptoms in Parkinson's disease |
Q28282629 | Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations |
Q38100484 | Movement disorders in cerebrovascular disease |
Q38176606 | Neural and behavioral substrates of subtypes of Parkinson's disease |
Q28067803 | Neuroanatomical changes in Parkinson's disease in relation to cognition: An update |
Q38847385 | Neuromuscular Impairments Are Associated With Impaired Head and Trunk Stability During Gait in Parkinson Fallers |
Q34489109 | Neuropsychiatry of the basal ganglia |
Q40253420 | Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis |
Q37243484 | Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy |
Q35013928 | Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease |
Q33636631 | New small molecules for the treatment of Parkinson's disease |
Q48685391 | Nigral iron deposition occurs across motor phenotypes of Parkinson's disease |
Q47352832 | Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials |
Q48006609 | Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson's disease patients |
Q38727963 | Nonmotor features of Parkinson's disease subtypes |
Q48105952 | Nonmotor symptoms and health-related quality of life in early Parkinson's disease |
Q38419541 | Nonmotor symptoms in early- and advanced-stage Parkinson's disease patients on dopaminergic therapy: how do they correlate with quality of life? |
Q51937445 | Odor recognition memory is not independently impaired in Parkinson's disease. |
Q35897340 | Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease |
Q47746039 | Pain Correlates with Sleep Disturbances in Parkinson's Disease Patients |
Q35756309 | Pain in Parkinson's Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life. |
Q38763507 | Parkinson Disease: The Relationship Between Non-motor Symptoms and Motor Phenotype |
Q37385032 | Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations |
Q92932663 | Parkinson patients without tremor show changed patterns of mechanical muscle oscillations during a specific bilateral motor task compared to controls |
Q34442161 | Parkinson subtypes progress differently in clinical course and imaging pattern |
Q58583813 | Parkinson's Disease Motor Subtypes Show Different Responses to Long-Term Subthalamic Nucleus Stimulation |
Q50239577 | Parkinson's Disease Subtypes Show Distinct Tradeoffs Between Response Initiation and Inhibition Latencies. |
Q37044196 | Parkinson's Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort |
Q54072241 | Parkinson's disease |
Q89938003 | Parkinson's disease as a multisystem disorder |
Q43815096 | Parkinson's disease beyond 20 years |
Q27686837 | Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies |
Q43544818 | Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. |
Q33644318 | Parkinson's disease subtypes show a specific link between dopaminergic and glucose metabolism in the striatum |
Q73503025 | Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis |
Q48166867 | Parkinson-related genetics in patients treated with deep brain stimulation |
Q40098767 | Parkinsonian patients show impaired predictive smooth pursuit |
Q39875586 | Parkinsonian single fallers versus recurrent fallers: different fall characteristics and clinical features |
Q34596340 | Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back |
Q35977440 | Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism |
Q47099085 | Patterns of grey matter loss associated with motor subscores in early Parkinson's disease. |
Q64859341 | Patterns of striatal and cerebellar functional connectivity in early-stage drug-naïve patients with Parkinson's disease subtypes |
Q48632126 | Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease |
Q30471148 | Pedunculopontine nucleus deep brain stimulation in Parkinson's disease. |
Q37755118 | Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration. |
Q64776556 | Periventricular White Matter Abnormalities on Diffusion Tensor Imaging of Postural Instability Gait Disorder Parkinsonism |
Q36847313 | Pharmacologic treatment of anxiety disorders in Parkinson disease |
Q36885018 | Phasic muscle activity in sleep and clinical features of Parkinson disease |
Q37717401 | Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters |
Q51802397 | Physical assessment as a predictor of mortality in people with Parkinson's disease: a study over 7 years. |
Q41717962 | Plasma antioxidant status and motor features in de novo Chinese Parkinson's disease patients |
Q50271729 | Positive family history of essential tremor influences the motor phenotype of Parkinson's disease. |
Q90194740 | Postural Instability in Parkinson's Disease: A Review |
Q50751729 | Postural instability and cognitive dysfunction in early Parkinson's disease. |
Q34306751 | Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management |
Q34140991 | Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis |
Q44307749 | Postural sway and falls in Parkinson's disease: a regression approach |
Q35671020 | Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease |
Q42996724 | Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study |
Q38669168 | Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts |
Q40240247 | Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort |
Q37329479 | Predictors of cognitive decline in the early stages of Parkinson's disease: a brief cognitive assessment longitudinal study. |
Q34531319 | Predictors of cognitive impairment in an early stage Parkinson's disease cohort |
Q57299928 | Predictors of self-perceived stigma in Parkinson's disease |
Q47549706 | Prescribing Pattern for Parkinson's Disease in Indian Community before Referral to Tertiary Center |
Q36226842 | Prevalence and pattern of perceived intelligibility changes in Parkinson's disease. |
Q36226461 | Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. |
Q48129611 | Primary sleep disorder prevalence in patients with newly diagnosed Parkinson’s disease |
Q51624298 | Probabilistic subgroup identification using Bayesian finite mixture modelling: a case study in Parkinson's disease phenotype identification. |
Q48174151 | Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT. |
Q50245993 | Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype |
Q39956114 | Progression of motor and nonmotor features of Parkinson's disease and their response to treatment |
Q37974751 | Progression of motor symptoms in Parkinson's disease |
Q38982712 | Progression of postural changes in Parkinson's disease: quantitative assessment. |
Q48846072 | Psychiatric symptoms screening in the early stages of Parkinson's disease |
Q35982851 | Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease |
Q40291225 | Quantitative measurement of Parkinsonian gait from walking in monocular image sequences using a centroid tracking algorithm |
Q90192046 | Quantitative susceptibility mapping in atypical Parkinsonisms |
Q36470291 | REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers |
Q48236738 | Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease |
Q37576274 | Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease? |
Q34160166 | Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis |
Q55315190 | Recurrence Quantification Analysis at work: Quasi-periodicity based interpretation of gait force profiles for patients with Parkinson disease. |
Q38498994 | Reduced verbal fluency for proper names in nondemented patients with Parkinson's disease: A quantitative and qualitative analysis |
Q36374541 | Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease |
Q64787870 | Regional gray matter changes and age predict individual treatment response in Parkinson's disease. |
Q49152212 | Regional homogeneity alterations differentiate between tremor dominant and postural instability gait difficulty subtypes of Parkinson's disease |
Q50242405 | Relationship between [123 I]-FP-CIT SPECT and clinical progression in Parkinson's disease |
Q50241117 | Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease |
Q37559997 | Repeatable battery for assessment of neuropsychological status in early Parkinson's disease |
Q52646700 | Rescuing Suboptimal Patient-Reported Outcome Instrument Data in Clinical Trials: A New Strategy. |
Q89912027 | Research-based Updates in Swallowing and Communication Dysfunction in Parkinson Disease: Implications for Evaluation and Management |
Q67216108 | Responses to dynamic head-and-body tilts are enhanced in Parkinson's disease. |
Q33805431 | Rest tremor revisited: Parkinson's disease and other disorders. |
Q40754046 | Resting-state functional connectivity of dentate nucleus is associated with tremor in Parkinson's disease |
Q44976807 | Revisiting the relationship between essential tremor and Parkinson's disease |
Q43827118 | Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patients |
Q45071354 | Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial |
Q64090393 | Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study |
Q33996828 | Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. |
Q48685847 | Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. |
Q45820322 | Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease |
Q91878144 | Sex specific cognitive differences in Parkinson disease |
Q41547487 | Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinson's disease |
Q35692655 | Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers |
Q37681251 | Sleep disturbances in Parkinson disease and their potential role in heterogeneity |
Q37593728 | Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's |
Q51949307 | Stability and Change in Patterns of Coping with Parkinson's Disease |
Q36055434 | Structural Brain Alterations in Motor Subtypes of Parkinson's Disease: Evidence from Probabilistic Tractography and Shape Analysis |
Q39006054 | Structural and physiological neurovascular changes in idiopathic Parkinson's disease and its clinical phenotypes |
Q48252241 | Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease |
Q37161380 | Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans |
Q37080947 | Subcortical Volumes Differ in Parkinson's Disease Motor Subtypes: New Insights into the Pathophysiology of Disparate Symptoms |
Q48485654 | Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease |
Q93170343 | Subthalamic nucleus oscillations correlate with vulnerability to freezing of gait in patients with Parkinson's disease |
Q38889950 | Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression? |
Q92673232 | Subtypes of Sleep Disturbance in Parkinson's Disease Based on the Cross-Culturally Validated Korean Version of Parkinson's Disease Sleep Scale-2 |
Q90599581 | Subtyping of Parkinson's Disease - Where Are We Up To? |
Q37077841 | Susceptibility-weighted MRI of extrapyramidal brain structures in Parkinsonian disorders |
Q41979984 | Syndromic approach to Parkinson's disease: role of functional imaging |
Q48684704 | Systemic administration of MPTP induces thalamic neuronal degeneration in mice |
Q54960563 | TOWARD AN OBJECTIVE METHOD TO CLASSIFY TREMOR DOMINANT AND POSTURAL INSTABILITY AND GAIT DIFFICULTY SUBTYPES OF PARKINSON'S DISEASE: A PILOT STUDY. |
Q64795547 | Thalamic and ventricular volumes predict motor response to deep brain stimulation for Parkinson's disease |
Q28660352 | The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T |
Q41385135 | The Association Between Parkinson's Disease Motor Impairments and Pain |
Q28076121 | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort |
Q92071163 | The Effect of Medication and Deep Brain Stimulation on Posture in Parkinson's Disease |
Q39681041 | The Evolution of REM Sleep Behavior Disorder in Early Parkinson Disease |
Q46099687 | The Initial Symptom and Motor Progression in Spinocerebellar Ataxias |
Q37338662 | The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group |
Q34748298 | The Mini-BESTest--a clinically reproducible tool for balance evaluations in mild to moderate Parkinson's disease? |
Q35098556 | The Natural History of Depression in Parkinson's Disease within 30-Month Follow-Up. |
Q48930513 | The Neural Basis of Postural Instability Gait Disorder Subtype of Parkinson's Disease: A PET and fMRI Study. |
Q38944057 | The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. |
Q58720353 | The Prevalence of Cerebral Microbleeds in Non-Demented Parkinson's Disease Patients |
Q46252722 | The Results, Indications, and Physiology of Posteroventral Pallidotomy for Patients with Parkinson's Disease |
Q38817900 | The Stroop Color and Word Test |
Q64107358 | The Ventral Intermediate Nucleus Differently Modulates Subtype-Related Networks in Parkinson's Disease |
Q48941906 | The association between motor subtypes and alexithymia in de novo Parkinson's disease. |
Q55068946 | The cholinergic contribution to the resting-state functional network in non-demented Parkinson's disease. |
Q31008210 | The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature |
Q48483729 | The heterogeneity of cognitive symptoms in Parkinson's disease: a meta-analysis |
Q34925276 | The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients |
Q55217205 | The impact of walking speed on interlimb coordination in individuals with Parkinson's disease. |
Q92262951 | The influence of initial symptoms on phenotypes in spinocerebellar ataxia type 3 |
Q30586911 | The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa |
Q47597261 | The natural history of depressive symptoms in patients with incident Parkinson's disease: a prospective cohort study |
Q34255674 | The pathophysiology of tremor |
Q30426047 | The pattern of striatal dopaminergic denervation explains sensorimotor synchronization accuracy in Parkinson's disease |
Q37968092 | The phenomenology of parkinsonian tremor |
Q48107415 | The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease |
Q43944347 | The prevalence of Parkinson's disease in rural Tanzania |
Q37690360 | The progression of pathology in Parkinson's disease |
Q42604425 | The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease |
Q35566358 | The relation between depression and parkin genotype: the CORE-PD study |
Q56525924 | The role of substantia nigra sonography in the differentiation of Parkinson's disease and multiple system atrophy |
Q38100518 | The role of the cerebellum in the pathophysiology of Parkinson's disease. |
Q41642605 | The significance of motor (a)symmetry in Parkinson's disease. |
Q36659353 | The spectrum of nonmotor symptoms in early Parkinson disease |
Q35452958 | The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years |
Q33992654 | The use of dopamine agonists in very elderly patients with Parkinson's disease |
Q61812347 | Tonic Neuromuscular Processing Affects Postural Adaptation Differently in Aging and Parkinson's Disease |
Q46663623 | Toward automated, at-home assessment of mobility among patients with Parkinson disease, using a body-worn accelerometer |
Q31008758 | Tracking Parkinson's: Study Design and Baseline Patient Data |
Q38654730 | Transcranial sonography image characteristics in different Parkinson's disease subtypes |
Q38063341 | Treatment in early Parkinson's disease: the Norwegian ParkWest study. |
Q46643603 | Treatment of dementia with Lewy bodies and Parkinson's disease dementia |
Q37685691 | Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists |
Q50665272 | Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening. |
Q50506611 | Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease. |
Q91880841 | Unveiling the relationship between central parkinsonian pain and motor symptoms in Parkinson's disease |
Q92002128 | Update on the Management of Parkinson's Disease for General Neurologists |
Q60950147 | Updating Our Definitions of Parkinson's Disease for a Molecular Age |
Q42876832 | Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease |
Q35923957 | Using Accelerometer and Gyroscopic Measures to Quantify Postural Stability. |
Q38429832 | Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease |
Q40902411 | Vascular Risk Factors and Cognition in Parkinson's Disease |
Q50266619 | Vascular risk factors and the effect of white matter lesions on extrapyramidal signs in Alzheimer's disease. |
Q37357571 | Visual hallucinations in posterior cortical atrophy |
Q38807003 | Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease |
Q37243463 | Voxel-based morphometry in autopsy proven PSP and CBD |
Q28554041 | Weight Change Is a Characteristic Non-Motor Symptom in Drug-Naïve Parkinson's Disease Patients with Non-Tremor Dominant Subtype: A Nation-Wide Observational Study |
Q35459164 | What contributes to quality of life in patients with Parkinson's disease? |
Q28083203 | What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic? |
Q37015538 | Which Aspects of Postural Control Differentiate between Patients with Parkinson's Disease with and without Freezing of Gait? |
Q35434976 | Which measures of physical function and motor impairment best predict quality of life in Parkinson's disease? |
Q34576193 | White matter hyperintensities in Parkinson's disease: do they explain the disparity between the postural instability gait difficulty and tremor dominant subtypes? |
Q50240007 | White matter microstructure damage in tremor-dominant Parkinson's disease patients |
Q35042213 | Widespread increase of functional connectivity in Parkinson's disease with tremor: a resting-state FMRI study |
Search more.